Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

January 26, 2026

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

November 19, 2025

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

November 5, 2025

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

October 21, 2025

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

August 14, 2025

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

May 13, 2025

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

February 25, 2025

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

November 5, 2024

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

August 6, 2024

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

May 1, 2024

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

123 4 5...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top